189 related articles for article (PubMed ID: 4049312)
1. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma".
Cerletti C; Latini R; Del Maschio A; Galletti F; Dejana E; de Gaetano G
Thromb Haemost; 1985 Jun; 53(3):415-8. PubMed ID: 4049312
[TBL] [Abstract][Full Text] [Related]
2. The absorption of acetylsalicylic acid from an enteric-coated formulation and the inhibition of thromboxane formation.
Anttila M; Kahela P; Uotila P
Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):88-92. PubMed ID: 3410591
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function.
Cerletti C; Bonati M; del Maschio A; Galletti F; Dejana E; Tognoni G; de Gaetano G
J Lab Clin Med; 1984 Jun; 103(6):869-77. PubMed ID: 6726057
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology].
Castel JM; Artaza MA; Laporte JR
Med Clin (Barc); 1991 May; 96(18):689-91. PubMed ID: 2072775
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
[TBL] [Abstract][Full Text] [Related]
6. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans.
Cerletti C; Marchi S; Lauri D; Domanin M; Lorenzi G; Urso R; Dejana E; Latini R; de Gaetano G
Clin Pharmacol Ther; 1987 Aug; 42(2):175-80. PubMed ID: 3301151
[TBL] [Abstract][Full Text] [Related]
8. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2.
FitzGerald GA; Lupinetti M; Charman SA; Charman WN
J Pharmacol Exp Ther; 1991 Dec; 259(3):1043-9. PubMed ID: 1762060
[TBL] [Abstract][Full Text] [Related]
9. Peripheral venous plasma aspirin concentrations and platelet aggregation inhibition produced by enteric-coated aspirin formulations.
Brandon RA; Emmett JA; Eadie MJ; Curran AC; Bunce IH
Thromb Haemost; 1986 Apr; 55(2):222-7. PubMed ID: 3715789
[TBL] [Abstract][Full Text] [Related]
10. Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
Postula M; Janicki PK; Rosiak M; Przybylkowski A; Kaplon-Cieslicka A; Grygorowicz T; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
Cardiol J; 2013; 20(2):170-7. PubMed ID: 23558875
[TBL] [Abstract][Full Text] [Related]
11. Intravenous acetylsalicylic acid--dose-related effects on platelet function and fibrinolysis in healthy males.
Husted SE; Kristensen SD; Vissinger H; Mørn B; Schmidt EB; Nielsen HK
Thromb Haemost; 1992 Aug; 68(2):226-9. PubMed ID: 1412171
[TBL] [Abstract][Full Text] [Related]
12. Effect of transdermic acetylsalicylic acid on hemostasis in healthy volunteers.
Martínez AB; Funosas E; Maestri L; Lucena PH
Acta Odontol Latinoam; 2007; 20(1):3-8. PubMed ID: 18046964
[TBL] [Abstract][Full Text] [Related]
13. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
[TBL] [Abstract][Full Text] [Related]
14. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
Patrick J; Dillaha L; Armas D; Sessa WC
Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
[TBL] [Abstract][Full Text] [Related]
16. Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclooxygenase activity is reduced by portacaval shunt in rats.
Gambino MC; Passaghe S; Chen ZM; Bucchi F; Gori G; Latini R; de Gaetano G; Cerletti C
J Pharmacol Exp Ther; 1988 Apr; 245(1):287-90. PubMed ID: 3129553
[TBL] [Abstract][Full Text] [Related]
17. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
18. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase.
McAdam B; Keimowitz RM; Maher M; Fitzgerald DJ
J Pharmacol Exp Ther; 1996 May; 277(2):559-64. PubMed ID: 8627531
[TBL] [Abstract][Full Text] [Related]
19. Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin.
Scavone M; Rizzo J; Femia EA; Podda GM; Bossi E; Caberlon S; Paroni R; Cattaneo M
Thromb Haemost; 2020 Oct; 120(10):1442-1453. PubMed ID: 32717754
[TBL] [Abstract][Full Text] [Related]
20. Umbilical cord serum levels of thromboxane B2 in term infants of women who participated in a placebo-controlled trial of low-dose aspirin.
Parker CR; Hauth JC; Goldenberg RL; Cooper RL; Dubard MB
J Matern Fetal Med; 2000; 9(4):209-15. PubMed ID: 11048830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
